0000950170-24-088537.txt : 20240731
0000950170-24-088537.hdr.sgml : 20240731
20240731160507
ACCESSION NUMBER: 0000950170-24-088537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240729
FILED AS OF DATE: 20240731
DATE AS OF CHANGE: 20240731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mancini Marianna
CENTRAL INDEX KEY: 0001838112
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 241161873
MAIL ADDRESS:
STREET 1: C/O VIKING THERAPEUTICS, INC.
STREET 2: 12340 EL CAMINO REAL, STE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-07-29
0001607678
Viking Therapeutics, Inc.
VKTX
0001838112
Mancini Marianna
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
false
true
false
false
Chief Operating Officer
false
Common Stock, par value $0.00001 per share
2024-07-29
4
A
false
10000
0
A
358508
D
Common Stock, par value $0.00001 per share
2024-07-29
4
A
false
21667
0
A
380175
D
Common Stock, par value $0.00001 per share
2024-07-30
4
S
false
14704
56.98
D
365471
D
Common Stock, par value $0.00001 per share
2024-07-30
4
S
false
3322
57.82
D
362149
D
The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $57.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.51 to $58.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Michael Morneau as Attorney-in-Fact
2024-07-31